Guidelines for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes
Michelle D. Kelsey(Duke University), Neha J. Pagidipati(Duke University), Christopher B. Granger(Clinical Research Institute), Eric D. Peterson(The University of Texas Southwestern Medical Center), Darren K. McGuire(Parkland Health & Hospital System), Adam J. Nelson(Clinical Research Institute), Jennifer B. Green
Cited by 95
Related Papers
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
An Updated Definition of Stroke for the 21st Century
|Stroke|2013|3.5k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation
|New England Journal of Medicine|2019|1.9k